Timolol
- Generic Name
- Timolol
- Brand Names
- Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
- Drug Type
- Small Molecule
- Chemical Formula
- C13H24N4O3S
- CAS Number
- 26839-75-8
- Unique Ingredient Identifier
- 5JKY92S7BR
- Background
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions su...
- Indication
Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
- Associated Therapies
- -
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia
- Conditions
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2021-02-02
- Target Recruit Count
- 267
- Registration Number
- NCT00751062
- Locations
- 🇸🇪
Pfizer Investigational Site, Uppsala, Sweden
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2021-02-03
- Target Recruit Count
- 139
- Registration Number
- NCT00716859
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Comparison of Latanoprost Vs. Timolol
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 30
- Registration Number
- NCT00579969
- Locations
- 🇺🇸
UNMC Department of Ophthalmolgy and Visual Sciences, Omaha, Nebraska, United States
Circadian Rhythms of Aqueous Humor Dynamics in Humans
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 30
- Registration Number
- NCT00572936
- Locations
- 🇺🇸
University of Nebraska Medical Center, Department of Ophthalmolgy and Visual Sciences, Omaha, Nebraska, United States
Beta Blocker for Chronic Wound Healing
- First Posted Date
- 2006-08-25
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 40
- Registration Number
- NCT00368602
- Locations
- 🇺🇸
VA Medical Center, Mather, California, United States
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
- Conditions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2021-02-18
- Target Recruit Count
- 528
- Registration Number
- NCT00277498
- Locations
- 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States
Assessing Cosopt Switch Patients
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2008-11-19
- Lead Sponsor
- Pharmaceutical Research Network
- Target Recruit Count
- 60
- Registration Number
- NCT00273442
- Locations
- 🇺🇸
Little Rock Eye Clinic, Little Rock, Arkansas, United States
🇺🇸Omni Eye Services, Atlanta, Georgia, United States
🇺🇸Glaucoma Consultants & Center for Eye Research, Mt. Pleasant, South Carolina, United States
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2021-02-21
- Target Recruit Count
- 500
- Registration Number
- NCT00159653
- Locations
- 🇨🇦
Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada
Prevention of Esophageal Varices by Beta-Adrenergic Blockers
- Conditions
- Interventions
- First Posted Date
- 2000-10-06
- Last Posted Date
- 2017-06-01
- Target Recruit Count
- 213
- Registration Number
- NCT00006398
- Locations
- 🇬🇧
Royal Free Hospital, Hampstead, London, United Kingdom
🇺🇸The Faulkner Hospital, Boston, Massachusetts, United States
🇪🇸Hospital Clinic I Provincial de Barcelona, Barcelona, Catalonia, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.